Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
August 04 2023 - 7:00AM
Business Wire
Omeros Corporation (NASDAQ: OMER), today announced that the
company will issue its financial results for the quarter ended June
30, 2023, on Wednesday, August 9, 2023, before the market opens.
Omeros management will host a conference call and webcast that same
day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss
the financial results as well as recent developments and
highlights.
Conference Call Details
For online access to the live webcast of the conference call, go
to Omeros’ website at
https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must
register at this link to receive a unique PIN. Once registered, you will have two options: (1)
Dial in to the conference line provided at the registration site
using the PIN provided to you, or (2) choose the “Call Me” option,
which will instantly dial the phone number you provide. Should you
lose your PIN or registration confirmation email, simply
re-register to receive a new PIN.
A replay of the call will be made accessible online at
https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy (TA-TMA).
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome.
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing across multiple clinical programs for alternative
pathway-related diseases, including paroxysmal nocturnal
hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more
information about Omeros and its programs, visit
www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230804405041/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2024 to May 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From May 2023 to May 2024